The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
L | Antineoplastic and immunomodulating agents | |
2
|
L04 | Immunosuppressants | |
3
|
L04A | Immunosuppressants | |
4
|
L04AC | Interleukin inhibitors | |
5
|
L04AC16 |
| Active Ingredient |
|---|
|
Guselkumab is a human IgG1λ monoclonal antibody (mAb) that binds selectively to the interleukin 23 (IL-23) protein with high specificity and affinity. IL-23 is a cytokine that is involved in inflammatory and immune responses. By blocking IL-23 from binding to its receptor, guselkumab inhibits IL-23-dependent cell signalling and release of proinflammatory cytokines. |
| Document | Type | Information Source | |
|---|---|---|---|
| TREMFYA Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| TREMFYA Solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.